Experimental Evaluation of a New Tissue Factor-Based Topical Hemostat (TT-173) for Treatment of Hepatic Bleeding

References

• Sitzmann JV, Greene PS. Perioperative predictors of morbidity following hepatic resection for neoplasm. A multivariate analysis of a single surgeon experience with 105 patients. Ann Surg. 1994;219(1):13–17.
   PubMed Web of Science ®Google Scholar
• Delis SG, Bakoyiannis A, Tassopoulos N, Athanasiou K, Madariaga J, Dervenis C. Radiofrequency-assisted liver resection. Surg Oncol. 2008;17(2):81–86.
   PubMed Web of Science ®Google Scholar
• Balaa FK, Gamblin TC, Tsung A, Marsh JW, Geller DA. Right hepatic lobectomy using the staple technique in 101 patients. J Gastrointest Surg. 2008;12(2):338–343.
   PubMed Web of Science ®Google Scholar
• Mueller GR, Wolf RF, Hansen PD, Gregory KW, Prahl SA. Hemostasis after liver resection improves after single application of albumin and argon beam coagulation. J Gastrointest Surg. 2010;14(11):1764–1769.
   PubMed Web of Science ®Google Scholar
• Ruitenbeek K, Ayez N, Verhoef C, et al. Safety and efficacy of a novel, dry powder fibrin sealant for hemostasis in hepatic resection. Dig Surg. 2014;31(6):422–427.
   PubMed Web of Science ®Google Scholar
• Koea JB, Batiller J, Aguirre N, et al. A multicentre, prospective, randomized, controlled trial comparing EVARREST™ fibrin sealant patch to standard of care in controlling bleeding following elective hepatectomy: anatomic versus non-anatomic resection. HPB (Oxford). 2016;18(3):221–228.
   PubMed Web of Science ®Google Scholar
• Genyk Y, Kato T, Pomposelli JJ, et al. Fibrin Sealant Patch (TachoSil) vs Oxidized Regenerated Cellulose Patch (Surgicel Original) for the secondary treatment of local bleeding in patients undergoing hepatic resection: a randomized controlled trial. J Am Coll Surg. 2016;222(3):261–268.
   PubMed Web of Science ®Google Scholar
• Gabay M, Boucher BA. An essential primer for understanding the role of topical hemostats, surgical sealants, and adhesives for maintaining hemostasis. Pharmacotherapy. 2013;33(9):935–955.
   PubMed Web of Science ®Google Scholar
• Shander A, Kaplan LJ, Harris MT, et al. Topical hemostatic therapy in surgery: bridging the knowledge and practice gap. J Am Coll Surg. 2014;219(3):570–5e4.
   PubMed Web of Science ®Google Scholar
• Fischer L, Seiler CM, Broelsch CE, et al. Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery. 2011;149(1):48–55.
   PubMed Web of Science ®Google Scholar
• Schwartz M, Madariaga J, Hirose R, et al. Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg. 2004;139(11):1148–1154.
   PubMedGoogle Scholar
• Izzo F, Di Giacomo R, Falco P, et al. Efficacy of a haemostatic matrix for the management of bleeding in patients undergoing liver resection: results from 237 cases. Curr Med Res Opin. 2008;24(4):1011–1015.
   PubMed Web of Science ®Google Scholar
• Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007;205(2):256–265.
   PubMed Web of Science ®Google Scholar
• Verhoef C, Singla N, Moneta G, et al. Fibrocaps for surgical hemostasis: two randomized, controlled phase II trials. J Surg Res. 2015;194(2):679–687.
   PubMed Web of Science ®Google Scholar
• Bochicchio GV, Gupta N, Porte RJ, et al. The FINISH-3 trial: a phase 3, international, randomized, single-blind, controlled trial of topical fibrocaps in intraoperative surgical hemostasis. J Am Coll Surg. 2015;220(1):70–81.
   PubMed Web of Science ®Google Scholar
• Frilling A, Stavrou GA, Mischinger HJ, et al. Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg. 2005;390(2):114–120.
   PubMed Web of Science ®Google Scholar
• Horowitz B, Busch M. Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin. Transfusion. 2008;48(8):1739–1753.
   PubMed Web of Science ®Google Scholar
• Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg. 2005;79(3):1037–1038.
   PubMed Web of Science ®Google Scholar
• Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001;233(1):88–96.
   PubMed Web of Science ®Google Scholar
• Berruyer M, Amiral J, Ffrench P, et al. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg. 1993;105(5):892–897.
   PubMed Web of Science ®Google Scholar
• Bänninger H, Hardegger T, Tobler A, et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol. 1993;85(3):528–532.
   PubMed Web of Science ®Google Scholar
• Rojas Codina S, Herance JR, Centeno A, et al. Nonclinical Evaluation of the New Topical Hemostatic Agent TT-173 for Skin Grafting Procedures. J Burn Care Res. 2017;38:e824–e833.
   PubMed Web of Science ®Google Scholar
• Rojas S, Herance JR, Gispert JD, et al. Characterization of the biodistribution and systemic absorption of TT-173, a new hemostatic agent of recombinant human tissue factor, using radiolabeling with 18F. Eur J Drug Metab Pharmacokinet. 2017;42(4):583–592.
   PubMed Web of Science ®Google Scholar
• López-López J, Jané-Salas E, Santamaría A, et al. TETIS study: evaluation of new topical hemostatic agent TT-173 in tooth extraction. Clin Oral Invest. 2016;20(5):1055–1063.
   PubMed Web of Science ®Google Scholar
• Rojas S, Pérez Del Caz MD, Esteban Vico JR, et al. EHTIC study: Evaluation of a new hemostatic agent based on tissue factor in skin grafting procedures. Burns. 2017;43(4):780–788.
   PubMed Web of Science ®Google Scholar
• Morse DC, Silva E, Bartrom J, et al. Improved bleeding scores using Gelfoam® Powder with incremental concentrations of bovine thrombin in a swine liver lesion model. J Thromb Thrombolysis. 2016;42(3):352–359.
   PubMed Web of Science ®Google Scholar
• Holcomb JB, McClain JM, Pusateri AE, et al. Fibrin sealant foam sprayed directly on liver injuries decreases blood loss in resuscitated rats. J Trauma. 2000;49(2):246–250.
   PubMedGoogle Scholar
• Lewis KM, Atlee H, Mannone A, Lin L, Goppelt A. Efficacy of hemostatic matrix and microporous polysaccharide hemospheres. J Surg Res. 2015;193(2):825–830.
   PubMed Web of Science ®Google Scholar
• Karakaya K, Ucan HB, Tascilar O, et al. Evaluation of a new hemostatic agent Ankaferd Blood Stopper in experimental liver laceration. J Invest Surg. 2009;22(3):201–206.
   PubMed Web of Science ®Google Scholar
• Lewis KM, Schiviz A, Hedrich HC, Regenbogen J, Goppelt A. Hemostatic efficacy of a novel, PEG-coated collagen pad in clinically relevant animal models. Int J Surg. 2014;12(9):940–944.
   PubMed Web of Science ®Google Scholar
• Jegatheeswaran S, Bhanot U, Siriwardena AK. In vivo evaluation of the chitosan-based haemostatic agent Omni-stat® in porcine liver resection and in liver injury. Eur Surg Res. 2012;49(2):73–79.
   PubMed Web of Science ®Google Scholar
• Lewis KM, Li Q, Jones DS, et al. Development and validation of an intraoperative bleeding severity scale for use in clinical studies of hemostatic agents. Surgery. 2017;161(3):771–781.
   PubMed Web of Science ®Google Scholar
• Adams GL, Manson RJ, Hasselblad V, Shaw LK, Lawson JH. Acute in-vivo evaluation of bleeding with Gelfoam plus saline and Gelfoam plus human thrombin using a liver square lesion model in swine. J Thromb Thrombolysis. 2009;28(1):1–5.
   PubMed Web of Science ®Google Scholar
• Kochan J, Schmidtová L, Sadloňová I, Murányi A, Zigová J, Múčková M. Hemostatic effect and distribution of new rhThrombin formulations in rats. Interdiscip Toxicol. 2014;7(4):219–222.
   PubMedGoogle Scholar
• Kawamura M, Sawafuji M, Watanabe M, Horinouchi H, Kobayashi K. Frequency of transmission of human parvovirus B19 infection by fibrin sealant used during thoracic surgery. Ann Thorac Surg. 2002;73(4):1098–1100.
   PubMed Web of Science ®Google Scholar
• Hino M, Ishiko O, Honda KI, et al. Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery. Br J Haematol. 2000;108(1):194–195.
   PubMed Web of Science ®Google Scholar
• Ballard JL, Weaver FA, Singla NK, Chapman WC, Alexander WA. Safety and immunogenicity observations pooled from eight clinical trials of recombinant human thrombin. J Am Coll Surg. 2010;210(2):199–204.
   PubMed Web of Science ®Google Scholar